Skip to main content
Log in

Use of somatostatin analog in management of carcinoid syndrome

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Carcinoid tumors are the most frequent gut neuroendocrine tumors accounting for more than 50% of all tumors of the gastroenteropancreatic (GEP) axis. These tumors appear to derive from a stem cell line capable of differentiating into a variety of malignant cells that secrete many different peptides and amines. The symptoms of carcinoid tumors are often non-specific, vague abdominal pain that may precede the diagnosis by a median of 9 years. Carcinoid syndrome occurs in <10% of patients. We evaluated the effects of SMS 201-995 in 14 such patients, 12 with diarrhea, 8 with flushing, 3 with wheezing, one with tricuspid valve incompetence, 6 with facial teleangiectasia, 3 with a pellagra type dermatosis and one with myopathy. Diarrhea was abolished or significantly reduced in 83%, flushing in 100%, wheezing in 100%, and myopathy improved in the one patient. Blood serotonin was resistant to change, urine 5HIAA fell in 75%, and most gut neuropeptide hormones apart from somatostatin were suppressed. Tumor growth appeared to be slowed in 2/3 of cases treated for up to 4 years. The analog of somatostatin appears to be a useful addition to the therapeutic armamentarium for carcinoid tumors and the symptom complex.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davis Z, Moertel CG, Mclirath DC: The malignant carcinoid syndrome. Surg Gynec Obstet 137:637–644, 1973

    PubMed  Google Scholar 

  2. Buchanan KD, Johnston CF, O'Hare MMT, et al: Neuroendocrine tumors. A European view. Am J Med 81 (Suppl 6b): 14–22, 1986

    PubMed  Google Scholar 

  3. Solcia E, Capella C, Buffa R, Frigerio B, Usellini L, Fiocca R: Morphological and functional classification of endocrine cells and related growths in the gastrointestinal tract.In Gastrointestinal Hormones. GBJ Glass (ed). New York, Raven Press, 1988, pp 1–17.

    Google Scholar 

  4. Weil C: Gastroenteropancreatic endocrine tumors. Klivo 63:433–459, 1985

    Google Scholar 

  5. Simpson S, Vinik AI, Marangos PJ, Lloyd RV: Immunohistochemical localization of neuron-specific enolase in gastroentero-pancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase. Cancer 54:1364, 1984

    PubMed  Google Scholar 

  6. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1:727–740, 1983

    PubMed  Google Scholar 

  7. Godwin JD II: Carcinoid tumors an analysis of 2837 cases. Cancer 36:560–569, 1975

    PubMed  Google Scholar 

  8. Strodel W, Vinik A, Thompson N, et al: Carcinoid tumors of the small intestine.In Endocrine Surgery Update. NW Thompson, AI Vinik (eds). New York, Grune & Stratton, 1983, pp 293–320

    Google Scholar 

  9. Melmon KL, Sjoerdsma A, Oates JA, Laster L: Treatment of malabsorption and diarrhea of carcinoid syndrome with methysergide. Gastroenterology 48:18, 1965

    PubMed  Google Scholar 

  10. Feldman JM: Urinary serotonin in the diagnosis of carcinoid tumor. Clin Chem 32:840–844, 1986

    PubMed  Google Scholar 

  11. Sandler M, Karim SMM, William ED: Prostaglandin in amine-peptide-secreting tumors. Lancet 2:1053–1055, 1968

    PubMed  Google Scholar 

  12. Alumets J, Hakanson R, Ingemannson S, Sundler F: Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid. Histochemistry 52:217, 1977

    PubMed  Google Scholar 

  13. Oates JA, Pettinger WA, Doctor RB: Evidence for the release of bradykinin in the carcinoid syndrome. J Clin Invest 45:173–178, 1966

    PubMed  Google Scholar 

  14. Pernow B, Waidenstrom J: Determination of 5-hydroxytryptamine, 5 hydrosyindolacetic acid and histamine in thirtythree cases of carcinoid tumor (argentaffinoma). Am J Med 34:255–260, 1985

    Google Scholar 

  15. Wilander E, Grimelius L, Portela-Gomes G, Sloan JM: Substance P and enteroglucagon-like immunoreactivity in argentaffin and argyrophil mid gut carcinoid tumors. Scand J Gastroenterol (suppl) 14:19–25, 1979

    Google Scholar 

  16. Strodel WE, Vinik AI, Jaffe BM, Eckhauzer F, Thompson NW: Substance P in the localization of a carcinoid tumor. J Surg Oncol 27:106–111, 1984

    PubMed  Google Scholar 

  17. Lucas KG, Feldman JM: Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 58:2290–2293, 1986

    PubMed  Google Scholar 

  18. Pernow B, Waldenstrom J: Determination of 5-hydroxytryptamine, 5-hydroxy indoleacetic acid and histamine in 33 cases of carcinoid (argentaffinoma). Am J Med 23:16–25, 1957

    PubMed  Google Scholar 

  19. Feldman JM: Increased dopamine production in patients with carcinoid tumors. Metabolism 34:255–260, 1985

    PubMed  Google Scholar 

  20. Theodrosson-Norheim E, Norheism KO, Brodin E, et al: Neuropeptide K: A major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun 131:77–83, 1985

    PubMed  Google Scholar 

  21. Vinik AI, Strodel WM, Lloyd RV: Unusual gastroenteropancreatic tumors and their hormones.In Endocrine Surgery Update. NW Thompson, AI Vinik (eds). New York, Grune & Stratton, 1983, pp 293–320

    Google Scholar 

  22. Feldman J, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81(suppl 6b):41–48, 1986

    PubMed  Google Scholar 

  23. Kvols LK: Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. Am J Med 81 (suppl 6b):49–55, 1986

    Google Scholar 

  24. Maton PN, Camilleri M, Griffin G, Hodgson H, Allison DJ, Chadwick VS: The role of hepatic arterial embolization in the carcinoid syndrome. Br Med J 287:932–935, 1983

    Google Scholar 

  25. Gyn NE, Kayasseh L, Keller IJ: VIP and watery diarrhea.In Gut Hormones, 2nd ed. SR Bloom, JM Polak (ed). Edinburgh, Churchill Livinston, 1981, pp 581–585

    Google Scholar 

  26. Sheppard M, Shapiro B, Primstone B, Kronhein S, Berelowitz M, Gregory M: Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48:50–53, 1979

    PubMed  Google Scholar 

  27. Bauer W, Briner U, Doepfner W, Waller R, Huguenin R, Marbach P, Fletcher TJ, Pless T: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140, 1982

    PubMed  Google Scholar 

  28. Walker TP: The determination of serotonin (5-hydroytryptamine) in human blood. J Lab Clin Med 55:824–829, 1959

    Google Scholar 

  29. Davis RB: The concentration of serotonin in normal human serum as determined by an improved method. J Lab Clin Med 54:344–351, 1959

    Google Scholar 

  30. Das ML: A rapid, sensitive method for direct estimation of serotonin in whole blood. Biochem Med 6:299–309, 1972

    PubMed  Google Scholar 

  31. Udenfriend C, Titus E, Weissbach H: The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J Biol Chem 216:499–505, 1955

    PubMed  Google Scholar 

  32. Vinik AI, Achem Karam S, Owyang C: Gastrointestinal hormones in clinical medicine.In Special Topics in Endocrinology and Metabolism, Vol 4. MP Cohen, PP Foa (eds). New York. Alan R. Liss, 1982, pp 93–138

    Google Scholar 

  33. Tsai ST, Lewis E, Vinik AI: The use of a somatostatin analogue in the management of the flushing syndrome. Scand J Gastroenterol 21(suppl 119):267–274, 1985

    Google Scholar 

  34. Frohlich J, Bloomgarden Z, Oates J, et al: The carcinoid flush provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299:1055–1057, 1978

    PubMed  Google Scholar 

  35. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn R: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666, 1986

    PubMed  Google Scholar 

  36. Richter G, Stockmann F, Lembeke B, Conlon JM, Creutzfeldt W: Short-term administration of somatostatin analogue SMS 20-1995 in patients with carcinoid tumors. Scand J Gastroenterol 21(suppl 119):193–198, 1986

    PubMed  Google Scholar 

  37. Kvols LK, Martin JK, Marsh HM, Moertel CG: Carcinoid crisis: Rapid reversal of the life-threatening hypotension with a somatostatin analogue. N Engl J Med 313:1229, 1985

    Google Scholar 

  38. Santangelo WC, O'Dorisio TM, Kim JG, Severino G, Krejs GJ: Pancreatic cholera syndrome—effect of a synthetic somatostatin analogue on intestinal water and ion transport. Ann Intern Med 103:363–367, 1985

    PubMed  Google Scholar 

  39. Vinik A, Tsai S, Moattarri A, Cheung P, Eckhauser F, Cho K: Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 81(suppl 6b):23–40, 1986

    Google Scholar 

  40. Arnold R, Lankisch: Somatostatin and the gastrointestinal tract. Clin Gastroenterol 9:733–754, 1980

    PubMed  Google Scholar 

  41. Stockmann F, Richter G, Lembcke B, Conlon JM, Creutzfeldt W: Long-term treatment of patients with endocrine gastrointestinal tumors with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 21 (suppl 119):230–237, 1986

    Google Scholar 

  42. Hengl G, Prager J, Pointner H: The influence of somatostatin on the absorption of triglycerides in partially gastrectomized subjects. Acta Hepato-Gastroenterol 26:392–395, 1979

    Google Scholar 

  43. Wood SM, Kraenzlin ME, Adrian TE, Bloom SR: Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide responses. Gut 26:438–444, 1985

    PubMed  Google Scholar 

  44. Poole CJM: Myelopathy secondary to metastatic carcinoid tumors. J Neurol Neurosurg Psychiatr 47:1359–1360, 1984

    PubMed  Google Scholar 

  45. Berry EM, Maunder C, Wilson M: Carcinoid myopathy and treatment with cyproheptadine (periactin). Gut 15:34–38, 1974

    PubMed  Google Scholar 

  46. Green D, Joynt RJ, Van Allen MW: Neuromyopathy associated with a malignant carcinoid tumor. Arch Intern Med 114:494–496, 1964

    PubMed  Google Scholar 

  47. Wroe SJ, Ardon M, Bouden AR: Myasthenia gravis associated with a hormone producing malignant carcinoid tumor. J Neurol Neurosurg Psychiat 48:719–720, 1985

    PubMed  Google Scholar 

  48. O'Stern WK, Barnard JL Jr, Yates RD: Morphologic changes in skeletal muscle induced by serotonin treatment, a light and electron microscopy study. Exp Mol Pathol 7:145–155, 1967

    PubMed  Google Scholar 

  49. Kraenzlin ME, Ching KC, Wood SM, Carr DH, Bloom SR: Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastorenterology 88:185–7, 1985

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vinik, A., Moattari, A.R. Use of somatostatin analog in management of carcinoid syndrome. Digest Dis Sci 34 (Suppl 3), S14–S27 (1989). https://doi.org/10.1007/BF01536042

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01536042

Key words

Navigation